September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
8 Diabetes Drug Updates
Liraglutide May Help Preserve BMD in Type 2 Diabetes
Treatment with liraglutide for 26 weeks had no impact on bone resorption in patients with T2D, say authors of a new study.
Dapagliflozin Granted FDA Priority Review for HFrEF
Dapagliflozin received FDA priority review for reducing risk of CV death in adults with heart failure with reduced ejection fraction.
Dapagliflozin Approved to Reduce Risk of Hospitalization for Heart Failure in T2D
The SGLT2 inhibitor, on October 21, 2019 was granted a label expansion from FDA for the prevention of hospitalization for heart failure in patients with T2D.
Glycemic Control Improves with Motivational Texts
For people with type 2 diabetes, receiving motivational messages via mobile text was associated with reduced A1c vs patients who received usual care.
Canagliflozin Approved to Slow CKD Progression in T2D
The SGLT-2 inhibitor canagliflozin was FDA-approved on September 30, 2019, to slow progression of diabetic kidney disease and reduce risk of heart failure hospitalization.
FDA Approves First Oral GLP-1 Receptor Agonist for T2D
Oral semaglutide, the first oral GLP-1 receptor agonsist, was approved by the FDA on Sept 20, 2019, becoming the only noninjectable formulation in the class.
Health of US Diabetes Patients Largely Unchanged since 2005
US adults with type 2 diabetes have acheived negligible change in blood glucose levels, blood pressure, LDL-C levels, and smoking status in the past 15 years, according to a new study.
PCPs are Missing Prediabetes, Survey Finds
Less than half of PCPs responding to a recent survey chose correct values for prediabetes screening tests and seemed unaware of other evidence-based recommendations for prediabetes.
Keeping Up with Coffee: A 6-question Health Quiz
What's your caffeine IQ? Test your knowledge on the latest caffeine research from its effect on cardiovascular disease to liver cancer with this brief quiz.
US Diabetes Treatment is Missing the Mark
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
Diabetes and the Flu: A Dangerous Duo
Help keep patients with diabetes healthy this flu season with a few of these quick reminders on vaccination, medication, comorbidities, and more.
Coffee Reconsidered: New Grounds for Drinking It
Caffeine moderation moderates cardiovascular risk, caffeine is not what is keeping you up at night, and 4 more recent studies on caffeine intake.
Diabetes Drug Costs Force Patients to Cut Corners
About 25% of patients with diabetes report asking a physician for a cheaper drug. Skipping doses and pill splitting are tactics used to cut costs.
New Approaches Improve Diagnosis, Prediction of Type 2 Diabetes
One US researcher notes that using A1c alone to classify diabetes may misdiagnose >33 million Americans. What are the other options and how well do they work? Read on.
Needle-free Hypoglycemia Treatment Approved
The novel intranasal glucagon delivered with a portable, single-use device could simplify treatment of this dangerous side effect of antidiabetes medications.
Treatment Intensification in Type 2 Diabetes: 3 Cases
When intensifying T2DM therapy to reach glycemic goals, newer agents target common comorbidities. Which would you choose in these 3 scenarios?
After Metformin: Which Class Would you Choose?
In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?
7 New Drugs for Primary Care: Q2 2019
The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about? Click through to find out.
The "Sweet Spot" in Type 2 Diabetes Management
The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.
Novel Dual-mechanism Agent Acts on Diabetes, Metabolic Complications
ADA 2019 ICYMI: Tirzepatide, a GIP and GLP-1 receptor agonist, reduces A1c and BMI as well as biomarkers of metabolic dysfunction in type 2 diabetes patients. Four studies reviewed.
First Oral GLP-1 Agonist Showcased while Approval Pending
ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials. Highlights, here.
Linagliptin Found Safe in T2DM Patients at High Cardiorenal Risk
ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.
SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
ADA 2019-Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.
Type 2 Diabetes: After the Diagnosis, Resist Inertia
Diabetes is a progressive disease and takes advantage of inaction. How would you manage our patient Mrs Davis?
Type 2 Diabetes: Clinical Suspicion and Diagnosis
Who is at risk for T2DM? How often should you screen? What are the cut offs for Dx? Revisit the basics in 5 minutes or less.
Treatment of Diabetes in Older Adults: Guideline Highlights
The Numbers: >90% of US adults aged ≥65 yrs have diabetes; 33% of those have T2DM; ~50% of older adults have prediabetes. We highlight new Endocrine Society treatment guidance.
Top 5 FDA-Cleared Apps for Primary Care
From a mobile EKG monitor to a digital urinalysis app, these medical "devices" are changing the way healthcare is delivered.
3 New Diabetes Studies, in Brief
Findings: a heart-healthy lifestyle reduces DM risk; 1 egg a day may protect against T2DM; and a new genetic risk score may improve DM diagnosis.
T2DM & Mental Illness: 9 Brain-Teasing Qs
True or false? The rates of T2DM in people with SMI are up to 5 times higher vs the general population.